Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LPCN | 8-K | bullish | 5/10 | Lipocine announced that Health Canada approved TLANDO (testosterone undecanoate) capsules for testosterone replacement t | Oct 7, 2026 |
| CUVL | 6-K | neutral | 2/10 | Clinuvel Pharmaceuticals Ltd filed a Form 6-K with the SEC on October 7, 2026, reporting that on October 5, 2026, it fil | Oct 7, 2026 |
| LITS | EFFECT | neutral | 3/10 | Lite Strategy, Inc. (LITS) received SEC effectiveness on its S-3 shelf registration (File No. 333-299169) as of October | Oct 7, 2026 |
| MAIA | EFFECT | bearish | 5/10 | The SEC declared effective MAIA Biotechnology's S-3 shelf registration (File No. 333-299148) on October 6, 2026. This al | Oct 7, 2026 |
| PBYI | SC 13D/A | neutral | 3/10 | Alan H. Auerbach, CEO and President of Puma Biotechnology, filed an amended Schedule 13D reporting that his 2011 warrant | Oct 6, 2026 |
| CNTB | SC 13G | neutral | 3/10 | BML Investment Partners, L.P. disclosed a 6.1% passive stake in Connect Biopharma Holdings Ltd via Schedule 13G, holding | Oct 6, 2026 |
| TTRX | 8-K | neutral | 5/10 | Turn Therapeutics released an updated investor presentation on October 6, 2026, detailing progress across its pipeline i | Oct 6, 2026 |
| SGMOQ | 25-NSE | bearish | 7/10 | Nasdaq has filed a Form 25-NSE to remove Sangamo Therapeutics' common stock from listing and registration, effective Oct | Oct 6, 2026 |
| AVIR | SC 13G | neutral | 4/10 | Tang Capital Management, led by Kevin Tang, filed a Schedule 13G converting its prior Schedule 13D status for Atea Pharm | Oct 6, 2026 |
| RAPP | 144 | bearish | 5/10 | CEO Abraham N. Ceesay filed a Form 144 to sell 39,470 shares of common stock valued at approximately $1.23 million, purs | Oct 6, 2026 |
| KYNB | 3 | neutral | 2/10 | Andrew E. Singer filed a Form 3 initial statement of beneficial ownership with Kyntra Bio, Inc., indicating he has becom | Oct 6, 2026 |
| RCKT | 8-K | bullish | 7/10 | Rocket Pharmaceuticals entered into a $150M senior secured credit facility with Hercules Capital, receiving an initial $ | Oct 6, 2026 |
| PMN | 3 | neutral | 2/10 | Ivana Rubino filed a Form 3 initial statement of beneficial ownership upon becoming Chief Commercial Officer of ProMIS N | Oct 6, 2026 |
| IVA | 6-K | neutral | 3/10 | Inventiva announced the presentation of three scientific abstracts at the upcoming AASLD The Liver Meeting 2026 (Novembe | Oct 6, 2026 |
| DARE | DEF 14A | bearish | 6/10 | Dare Bioscience is holding a special meeting on November 10, 2026 to seek stockholder approval for the potential issuanc | Oct 6, 2026 |
| IRLA | 8-K | neutral | 5/10 | Quince Therapeutics stockholders approved the 2026 Equity Incentive Plan (initial reserve of 821,872 shares plus up to 1 | Oct 6, 2026 |
| AURX | 8-K | neutral | 3/10 | Nuo Therapeutics closed the $325,000 Second Funding tranche under its existing Loan Agreement on October 6, 2026, bringi | Oct 6, 2026 |
| LKFT | 6-K | neutral | 2/10 | Lakefront Biotherapeutics disclosed the repurchase of 117,437 ordinary shares between September 28 and October 2, 2026, | Oct 6, 2026 |
| ACTU | S-1 | bearish | 7/10 | Actuate Therapeutics, a clinical-stage biopharmaceutical company developing elraglusib (a GSK-3 inhibitor for difficult- | Oct 6, 2026 |
| CRSP | 144 | neutral | 2/10 | James R. Kasinger, an officer of CRISPR Therapeutics AG, filed a Form 144 on October 6, 2026, indicating intent to sell | Oct 6, 2026 |
| SYRE | 424B5 | bearish | 6/10 | Spyre Therapeutics priced a $350M underwritten public offering of 4,117,648 shares of common stock at $85.00 per share, | Oct 6, 2026 |
| BCYC | 3/A | neutral | 1/10 | This is an amended Form 3 filing for Travis Thompson, CFO of Bicycle Therapeutics, correcting a prior omission of 980 or | Oct 6, 2026 |
| SNOA | 8-K | neutral | 3/10 | Sonoma Pharmaceuticals adopted a new Section 382 shareholder rights plan (poison pill) effective October 6, 2026, replac | Oct 6, 2026 |
| BYSI | 8-K | mixed | 6/10 | BeyondSpring completed the sale of its Chinese subsidiary (Bulin) to Biolin Investment Limited on September 30, 2026, re | Oct 6, 2026 |
| ONCY | DEFA14A | neutral | 2/10 | Oncolytics Biotech filed additional definitive proxy soliciting materials (DEFA14A) in connection with its upcoming Annu | Oct 6, 2026 |
| ONCY | DEF 14A | neutral | 3/10 | Oncolytics Biotech filed its definitive proxy statement for the 2026 Annual Meeting, seeking election of seven directors | Oct 6, 2026 |
| GRDX | S-1/A | bearish | 7/10 | GridAI Technologies Corp. filed Amendment No. 4 to its S-1 registration statement to register the resale of up to 9,908, | Oct 6, 2026 |
| PACB | 144 | bearish | 5/10 | Director James R. Gibson II filed a Form 144 notice of intent to sell up to 661,815 shares of Pacific Biosciences of Cal | Oct 6, 2026 |
| BMRN | 8-K | bearish | 6/10 | BioMarin disclosed that its Q3 2026 results will include ~$283M in pre-tax acquired IPR&D charges from the Alesta Therap | Oct 6, 2026 |
| ADPT | 144 | neutral | 2/10 | Susan Bobulsky, an officer of Adaptive Biotechnologies, filed a Form 144 on October 6, 2026, indicating intent to sell 6 | Oct 6, 2026 |